Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study.
about
Tumor stroma as targets for cancer therapyBeta 1-integrin-c-Met cooperation reveals an inside-in survival signalling on autophagy-related endomembranes.Tension in CancerIn vitro models of cancer stem cells and clinical applicationsIntegrins in cancer: biological implications and therapeutic opportunitiesβ₁Integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapyMicroRNA 9-3p targets β1 integrin to sensitize claudin-low breast cancer cells to MEK inhibitionHypoxia, inflammation, and the tumor microenvironment in metastatic diseaseIntegrins as "functional hubs" in the regulation of pathological angiogenesisExtracellular matrix molecules: potential targets in pharmacotherapy.Gene-based outcome prediction in multiple cohorts of pediatric T-cell acute lymphoblastic leukemia: a Children's Oncology Group study.Application of quantitative pharmacology in development of therapeutic monoclonal antibodiesA first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors.Steroid receptor coactivator-1 upregulates integrin α₅ expression to promote breast cancer cell adhesion and migrationIntegrin targeted therapeutics.A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer.β1-integrins signaling and mammary tumor progression in transgenic mouse models: implications for human breast cancer.Adrenomedullin expression in epithelial ovarian cancers and promotes HO8910 cell migration associated with upregulating integrin α5β1 and phosphorylating FAK and paxillin.Current knowledge on pancreatic cancer.Antiangiogenic therapy for glioma.Beta 1 integrin predicts survival in breast cancer: a clinicopathological and immunohistochemical study.Integrins and metastasis.β1 Integrin as a Prognostic and Predictive Marker in Triple-Negative Breast CancerMicroRNA-31 functions as a tumor suppressor and increases sensitivity to mitomycin-C in urothelial bladder cancer by targeting integrin α5.Therapeutic targets and new directions for antibodies developed for ovarian cancer.Prognostic value of β1 integrin expression in colorectal liver metastasesNovel strategies for the treatment of chondrosarcomas: targeting integrins.AKR1B10 promotes breast cancer metastasis through integrin α5/δ-catenin mediated FAK/Src/Rac1 signaling pathway.Targeting integrin α5β1 ameliorates severe airway hyperresponsiveness in experimental asthma.Antivascular agents for non-small-cell lung cancer: current status and future directions.Emerging anticancer therapeutic targets and the cardiovascular system: is there cause for concern?Tumor vasculature as target for therapeutic intervention.Environmental-mediated drug resistance: a target for multiple myeloma therapy.Critical comparison of MS and immunoassays for the bioanalysis of therapeutic antibodies.Targeting integrins in hepatocellular carcinoma.Therapeutic targeting of tumor-stroma interactions.Biotherapeutic first-in-human dose selection: making use of preclinical markers.Volociximab in cancer.A novel treatment for glioblastoma: integrin inhibition.Molecular targets in the discovery and development of novel antimetastatic agents: current progress and future prospects.
P2860
Q27015980-18CBBF85-3FF0-4939-A825-407C9B0F1A17Q27342529-5BE4F94D-7B5C-4427-8F36-EB986739FCC2Q28066437-2C204D76-8D53-4C34-8EB0-B5DC0BF75D9AQ28076101-8D4954B3-707B-4555-994D-B4D4FB913713Q29614536-4171B4A8-8F68-4D65-A9F0-35A8734B8008Q30427521-68D4E851-64C0-409B-A2E3-BEA53CAC886AQ30539640-20D57624-0CEE-401B-9ED0-B1C50F988874Q33576030-F1693328-FE5D-4D6A-A55A-1D1EF98486C6Q33591910-98009167-D172-441E-9A3B-1066B5049796Q33694487-515C7032-A99C-432A-81CD-DA99E20C31A9Q33888105-2EB765F4-59DC-4E18-B8B8-D1B4509E1BC7Q34293689-C93B5C99-D315-4FA1-B608-AF70F29F290DQ34403364-2EC8FD6D-DA18-428C-B90F-4BB5AC7D3CFAQ34789691-AAD3D565-F0F6-4373-97DC-F15A81FCC0AEQ34912684-AE3FCC8C-2780-4E1F-837B-3CE78123C85BQ35591666-81773764-E66C-4850-937C-E77375B033CCQ35889538-F613C7B4-1949-4534-BDCC-CC33C1D0E77AQ35914413-C50E6108-B44F-4B78-AFE7-2FA03FCE8883Q35971808-71DE78C1-D58D-493E-A8AE-3EDCB2BE7A3EQ36101999-A3E08A70-DF24-46A5-BC8C-EA29B04746B4Q36468724-925D70B6-11F7-40E4-9FDA-0DA6B627010EQ37014793-C4512C8A-32B3-401F-8B23-68FB1B0B4901Q37286353-4FB68E65-78E9-4F97-8E27-6262E6956BDAQ37317285-72A4A295-989D-448D-9C6A-4BF60D8D96EBQ37397674-E426900B-96CB-4E6D-80CC-EE37F54A8181Q37452274-1A3A91CF-22D3-41F8-AA4B-82EAA4C46655Q37486731-FDE03F82-E9DF-45CE-A4B7-2E0E992EAFC9Q37536701-09CAD524-492C-4349-ACCC-A41AB0264BCAQ37544994-9BA4132C-46F2-439E-8455-FE47B74C5233Q37624732-55D710DC-B3F6-4C90-A38B-049BFE334431Q37723147-964611ED-4509-42E9-A728-B20C819E9BE8Q37800110-1F016823-01DC-4D6C-B1F2-6F53548BE64DQ37810085-D4EF381D-5073-46EE-953D-26AA327A624DQ37810155-848DF8FD-351E-4548-A7AB-E2621AE7AE6EQ37844564-4AA4A29A-4158-48B1-976F-E0D14CAAAC96Q37851151-8419819C-4E64-496E-AF66-DC5894482615Q37960081-3C52A152-FD11-4FBB-9C59-B710D318B796Q37970775-FE74119B-AB38-455A-881C-9EE4DABFE927Q37997092-014CE191-B1A9-433B-AB2D-FED978690163Q38093654-9D2F7462-553F-4907-995B-2C1577666698
P2860
Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Volociximab, a chimeric monocl ...... biological correlative study.
@ast
Volociximab, a chimeric monocl ...... biological correlative study.
@en
type
label
Volociximab, a chimeric monocl ...... biological correlative study.
@ast
Volociximab, a chimeric monocl ...... biological correlative study.
@en
prefLabel
Volociximab, a chimeric monocl ...... biological correlative study.
@ast
Volociximab, a chimeric monocl ...... biological correlative study.
@en
P2093
P2860
P1476
Volociximab, a chimeric monocl ...... biological correlative study.
@en
P2093
Alejandro D Ricart
Anthony W Tolcher
Garry Schwartz
Geoffrey Weiss
Kyle Holen
Mark Albertini
Salim Yazji
P2860
P304
P356
10.1158/1078-0432.CCR-08-0378
P407
P577
2008-12-01T00:00:00Z